Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 76.63% is in line with its 2-year average of 74.65%, near the high end of its 2-year range (71.98%–77.10%).
0.89% above its 12-month average of 75.95%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 76.78%.
GROSS MARGIN
76.63%
GROSS MARGIN AVG TTM
75.95%
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.89%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 736 covered companies
CURRENT VS SECTOR MEDIAN
+88.60%
vs the sector median at left
Market Cap
$409.06M
Gross Margin
77.34%
TTM Avg
76.74%
3Y Avg
77.57%
5Y Avg
77.57%
Market Cap
$410.16M
Gross Margin
68.83%
TTM Avg
69.91%
3Y Avg
69.67%
5Y Avg
69.68%
Market Cap
$412.91M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
12.37%
Market Cap
$410.99M
Gross Margin
0.00%
TTM Avg
-125.52%
3Y Avg
-62.76%
5Y Avg
-41.84%
Market Cap
$414.16M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$395.51M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$419.87M
Gross Margin
61.77%
TTM Avg
80.89%
3Y Avg
90.44%
5Y Avg
-1369.52%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $406.14M | 76.63% | 75.95% | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $409.06M | 77.34% | 76.74% | 77.57% | 77.57% |
| Myriad Genetics, Inc. (MYGN)vs › | $410.16M | 68.83% | 69.91% | 69.67% | 69.68% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.91M | 0.00% | 0.00% | 0.00% | 12.37% |
| Neurogene Inc. (NGNE)vs › | $410.99M | 0.00% | -125.52% | -62.76% | -41.84% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $414.16M | 0.00% | 0.00% | 0.00% | 0.00% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $395.51M | 0.00% | 0.00% | 0.00% | 0.00% |
| REGENXBIO Inc. (RGNX)vs › | $390.83M | 88.09% | 73.91% | 64.55% | 70.68% |
| Prothena Corporation plc (PRTA)vs › | $419.87M | 61.77% | 80.89% | 90.44% | -1369.52% |
| Senseonics Holdings, Inc. (SENS)vs › | $421.28M | 44.71% | 23.54% | 19.38% | -46.55% |
Gross Margin
76.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 76.78% |
| 2026-03-31 | 77.10% |
| 2025-12-31 | 76.54% |
| 2025-09-30 | 75.93% |
| 2025-06-30 | 73.40% |
| 2025-03-31 | 74.94% |
| 2024-12-31 | 74.66% |
| 2024-09-30 | 72.81% |
| 2024-06-30 | 75.02% |
| 2024-03-31 | 72.04% |
| 2023-12-31 | 71.98% |
